Search

Displaying results 1631 - 1640 of 10000 in total
  1. Target

    Interleukin-17 receptor C

    go.drugbank.com/bio_entities/BE0017016
    TargetHumans

    Receptor for IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RA (PubMed:16785495). … Receptor for the heterodimer formed by IL17A and IL17B as part of a heterodimeric complex with IL17RA (PubMed:18684971).

    Polypeptides: Interleukin-17 receptor CSynonyms: IL-17 receptor C, Interleukin-17 receptor homolog
  2. Target

    Interleukin-17 receptor E

    go.drugbank.com/bio_entities/BE0017393
    TargetHumans

    Specific functional receptor for IL17C. May be signaling through the NF-kappa-B and MAPK pathways. May require TRAF3IP2 /ACT1 for signaling.

    Polypeptides: Interleukin-17 receptor ESynonyms: IL-17 receptor E
  3. Target

    Lysophosphatidic acid receptor 3

    go.drugbank.com/bio_entities/BE0020529
    TargetHumans

    Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. May play a role in the development of ovarian cancer.

    Polypeptides: Lysophosphatidic acid receptor 3Synonyms: LPA receptor 3, Lysophosphatidic acid receptor Edg-7
  4. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    ABL ratio on an international scale, with bosutinib treatment. … This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR

  5. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays … an important role in tumor cell growth and survival.

    Categories: Tropomyosin Receptor Kinases Inhibitors
  6. Drug

    Fostemsavir

    go.drugbank.com/drugs/DB11796
    ApprovedInvestigational

    [L14867] The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically … [A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant

  7. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    Hexylcaine has been discontinued in the US market. … Hexylcaine hydrochloride is also known as cyclaine and osmocaine. It is a short acting local anesthetic that acts through inhibition of sodium channels.

  8. Drug

    Chloroprocaine

    go.drugbank.com/drugs/DB01161
    ApprovedInvestigational

    [A252952] Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a preservative. … Chloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride.

  9. Drug

    Bromazepam

    go.drugbank.com/drugs/DB01558
    ApprovedIllicit

    One of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. … It is a intermediate-acting benzodiazepine.

  10. Drug

    Levacetylmethadol

    go.drugbank.com/drugs/DB01227
    ApprovedWithdrawn

    Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862] … Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.

    Categories: Drugs Used in Opioid Dependence, Drugs Used in Addictive Disorders